MedTrace Logo

A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas

NCT02302950 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 254

Last updated 2017-05-22

No results posted yet for this study

Summary

Raltegravir is the first marketed strand-transfer inhibitor of HIV-1 that was FDA approved in 2007. It is currently one of the preferred treatment regimens for HIV by the Department of Health and Human Services. It has become a widely used antiretroviral therapy option for HIV infected patients. It provides good tolerability and a favorable lipid profile for patients when compared to some other antiretroviral treatment options. Little data is reported about efficacy in a minority patient population. Moreover, data in an indigent minority population in the United States has not been aggregated before. Therefore this study will investigate the efficacy of raltegravir in minority women residing in Houston, TX who are HIV infected.

Conditions

  • HIV Infection

Interventions

DRUG

raltegravir

HIV therapy component

Sponsors & Collaborators

  • The University of Texas Health Science Center, Houston

    lead OTHER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2015-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02302950 on ClinicalTrials.gov